Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2017-06-06 Major Shareholding Noti…
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma plc : Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is explicitly titled 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES'. This form (TR-1) is used to notify the market when a person or entity acquires or disposes of a significant percentage of voting rights in a company, crossing specific notification thresholds. This directly corresponds to the definition of a Major Shareholding Notification. The filing details the change in ownership percentage (from a previous state to 6.16% and 5.65% for different share classes, totaling 11.81% in the resulting situation) for Novo A/S in Verona Pharma Plc. This aligns perfectly with the 'Major Shareholding Notification' category (MRQ).
2017-06-06 English
Verona Pharma plc : Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES' and details changes in voting rights thresholds crossed by 'Aisling Capital Management LP' and 'Aisling Capital IV LP' concerning shares in 'Verona Pharma plc'. This type of filing, which reports changes in significant share ownership (crossing thresholds like 3%), directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory form, MRQ is more specific than the general 'RNS' fallback.
2017-06-06 English
Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA
Regulatory Filings Classification · 95% confidence The document is a press release dated June 5, 2017, announcing the initiation of a clinical pharmacokinetic trial for the product candidate RPL554 following FDA IND acceptance. It details the study design, expected data timeline (Q4 2017), and includes standard forward-looking statements and contact information typical of corporate news releases. This content—announcing a specific operational/clinical development milestone—does not fit the definitions for 10-K, AR, ER, IR, or specific shareholder actions (DIV, DVA). It is a general corporate announcement regarding development progress. Since it is not a formal regulatory filing like a 10-K or a specific report (like an Audit Report or Earnings Release), and it is not a presentation (IP) or a transcript (CT), the most appropriate general category for a significant, non-standard corporate update that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for miscellaneous announcements distributed via wire services like Globenewswire.
2017-06-05 English
Exercise of Warrants and Total Voting Rights
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement disseminated via the RNS (Regulatory News Service) system, indicated by the 'RNS Number' and the footer 'This information is provided by RNS'. The content details the 'Exercise of Warrants and Total Voting Rights' and the resulting change in the total number of ordinary shares in issue (73,526,785). This type of announcement, which reports a specific corporate action affecting share capital and voting rights, fits best under the 'Share Issue/Capital Change' category (SHA) or potentially a general 'Regulatory Filing' (RNS). Since the core event is the issuance of new shares following warrant exercise, SHA is more specific than the general RNS fallback. However, the document explicitly mentions the total voting rights calculation denominator for FCA Disclosure and Transparency Rules, which is a regulatory disclosure. Given the options, 'SHA' (Share Issue/Capital Change) directly addresses the issuance of 1,000,000 New Ordinary Shares. If the primary focus was purely on the voting rights disclosure, DVA might be considered, but the capital change is the trigger. Since the document is a direct regulatory filing detailing a change in share capital, SHA is the most appropriate specific code.
2017-06-02 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is explicitly labeled with 'RNS Number : 8605G' and contains the header 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES'. This format is characteristic of regulatory notifications concerning changes in significant shareholdings, which aligns directly with the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general RNS fallback.
2017-06-01 English
Compassionate Use Programme and Trials Update
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the London Stock Exchange's news service (RNS). The content details updates on two clinical trials (STEM and SAS), including patient enrollment status, data monitoring board recommendations, and projected timelines for interim analysis and final read-out. This type of operational and clinical update, disseminated via RNS, is a general regulatory announcement. Since it is not a full financial report (10-K, IR), a specific earnings release (ER), or a formal proxy/governance document, the most appropriate classification is the general regulatory filing category, RNS.
2017-06-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.